<DOC>
	<DOCNO>NCT00787384</DOCNO>
	<brief_summary>The study perform ass : 1 ) clinical activity Imatinib patient HES , CEL CIH ; 2 ) correlation Imatinib activity specific disease subtype ; 3 ) long-term outcome HES , CEL CIH patient treat Imatinib ; 4 ) safety tolerability Imatinib administration .</brief_summary>
	<brief_title>Efficacy Imatinib Mesylate Hypereosinophilic Syndromes</brief_title>
	<detailed_description>Hypereosinophilic syndrome ( HES ) , chronic eosinophilic leukaemia ( CEL ) chronic idiopathic hypereosinophilia ( CIH ) rare disorder characterize chronic hypereosinophilia possible damage various organ due eosinophilic infiltration release cytokine . The therapy diseases largely unsatisfactory base use variety antiproliferative drug corticosteroid , interferon-alfa , cyclosporine , vincristine hydroxyurea . More often responses transient patient need numerous treatment line . In 2001 Schaller et al report first case patient HES resistant conventional treatment respond imatinib mesylate . ( Schaller , MGM 2001 ) . After , many author describe case hypereosinophilia achieve rapid response Imatinib 2003 Cools et al identify novel tyrosine kinase generate fusion Fip1-like 1 ( FIP1L1 ) gene PDGFRalfa gene associate hypereosinophilia . The optimal dose Imatinib setting patient still unknown ; however , demonstration effective safe clinical dos variety currently study malignant disease , suggest dose 100 mg/day increase weekly 100 mg/day ( maximum dose 400 mg/day ) , may employ . We design phase II trial investigate clinical anti-proliferative activity , safety tolerability escalate dos Imatinib ( entry dose 100 mg/d ) administer 12 total week HES , CEL CIH patient .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>patient diagnosis HES , CEL CIH , either previously untreated treated corticosteroid , cytotoxic drug , IFN . age &gt; 15 year . signature write informed consent ( parents/tutors patient age &lt; 18 year ) . patient diagnosis secondary hypereosinophilia age &lt; 15 year</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Hypereosinophilic syndrome ( HES )</keyword>
	<keyword>chronic eosinophilic leukaemia ( CEL )</keyword>
	<keyword>chronic idiopathic hypereosinophilia ( CIH )</keyword>
	<keyword>Imatinib</keyword>
	<keyword>Response</keyword>
	<keyword>Timing response</keyword>
</DOC>